{"id":416674,"date":"2026-02-09T19:40:47","date_gmt":"2026-02-09T19:40:47","guid":{"rendered":"https:\/\/www.newsbeep.com\/uk\/416674\/"},"modified":"2026-02-09T19:40:47","modified_gmt":"2026-02-09T19:40:47","slug":"roche-details-non-inferiority-of-btk-inhibitor-in-multiple-sclerosis-trial-endpoints-news","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/uk\/416674\/","title":{"rendered":"Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial &#8211; Endpoints News"},"content":{"rendered":"<p><a href=\"https:\/\/news.google.com\/rss\/articles\/CBMivAFBVV95cUxQZ3pSQnJTX0d1MWc2WENDTWltd1BybFRBSE5VSjNEZXczVjlKb3d1bmswenJPMnZWOG13S053emRDY3ppRkppSmpFVkxrQUFGbm9SNF9RMTNla1licWdnMjVuRVFoTURGMjYtRENlSnN5bkhPSTIzVVAwVlFGczdITmhJVFVYcjlkaWxzTXBIdmxnUEt5YjNkRFZFaTJWaWhiLUV1S19seElVR3h0TUFiMjZNZkU0bGRIckVjcg?oc=5\" target=\"_blank\" rel=\"nofollow noopener\">Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial<\/a>&nbsp;&nbsp;Endpoints News<a href=\"https:\/\/news.google.com\/rss\/articles\/CBMirgFBVV95cUxPbnFJZzRQbGxabFBYTFpjc3VKNFJqcjBENGRMeG51N0x6MTROVmNtNjJWUmxWd21LX01KTVUtN1BSY2liSW5BODd0MzFCNENFU2JzUkRnblp4blRXd2lPbXhoTGQxTUEweUZRNEY3UkdnZ1VQRGktZUJhSmpYWGpZNFRsbHBvNk9wWnUtSEg0aUFYLWIxTm15OXVQOWo5d2ZDSDdMYW9fTVNQZ1FnTmc?oc=5\" target=\"_blank\" rel=\"nofollow noopener\">Roche unveils data behind BTK inhibitor&#8217;s phase 3 multiple sclerosis win in Ocrevus trial<\/a>&nbsp;&nbsp;Fierce Biotech<a href=\"https:\/\/news.google.com\/rss\/articles\/CBMiigJBVV95cUxNUDMxd055cUZLYURUdzBMaWJMYWJOZEYwbExJaDRtcm4taVhaRWlnM3RJSmI4bUFka0dFVXQ5Mnh5Y19EQWFOWmhGUmxXZ25sQy1aX0t3UTlwRTlQNTBnLURJU2sxRWx4WDZUSmE3TkZCdi01NDBnMHE4S0hDazBOQWh4R2dkMkg3RnR6ZnlCVzcxaW54VV9TUnFoSzJaaHhoOC1yQXdxUjl2cGN3OVUtWWVvTnZudkJ4OUpkdk0wMktaQWYyVHN6X1lEdUVMb2RPcXAtUHBRQVo3VEFVOWtKNzV1Zmp2MFAzNWRrMmZYN1ZaRDZTX0U1dC1fOXV6Y1JpVlZVNFlUTHpLZw?oc=5\" target=\"_blank\" rel=\"nofollow noopener\">RO: Fenebrutinib matched ocrelizumab in slowing PPMS progression, with strong upper limb benefits<\/a>&nbsp;&nbsp;TradingView<a href=\"https:\/\/news.google.com\/rss\/articles\/CBMi7wFBVV95cUxNRDE4M3dmQlVCZW4tVG9naEFfMHhTT28xdkUzYkg2b21XUkpJYkNLSW16Nlh3UlFHNWNNZlBRQllUWXl2QnBkeU1oWjNRZnpuMUF2QVlKS2pjdHF0TS1IWHlNLXlQbHBRejVYVXM2N04yblhoZXhxZHpMN2J3aE5RYzdTS1l6YXk0NENvc1VBdWV3THlVYUF4bmJoRkh5WlhMSE9sZWlLZXNobjVjZnRGVVRCb3V0ZDBtTnVadmoyNzZxQkd1Zno5VUlYUGJlMlFsWHNvc0R1djJ1alNtUGxnYjZSN0paYldhNXV4akc3aw?oc=5\" target=\"_blank\" rel=\"nofollow noopener\">Roche&#8217;s multiple sclerosis drug fenebrutinib meets goal in late-stage trial<\/a>&nbsp;&nbsp;ET Pharma<a href=\"https:\/\/news.google.com\/rss\/articles\/CBMisAFBVV95cUxPalZBUnoxNWQ3bnI0bUtfTmt3Y2x2U0FqSVYyRFlhVnZLeEhGY3BKRUhWeTRKM19mTHY3alliaUsta2gyOWtUOGd4aklEeDhMYWVMYjc2dXB4OHpXcDRLQmNEMnhvWVRpdkFLU0lzNUpGall4dEdBOGNwbnd5NWFzR2hsRThNQXhBS1Q3MTMtTDNWS0F1djBPTk1JMFJvcG91V2M3bHMxVUVEMkZfeUtZVQ?oc=5\" target=\"_blank\" rel=\"nofollow noopener\">ACTRIMS 2026: Fenebrutinib matches Ocrevus in PPMS trial<\/a>&nbsp;&nbsp;Multiple Sclerosis News Today<\/p>\n","protected":false},"excerpt":{"rendered":"Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial&nbsp;&nbsp;Endpoints NewsRoche unveils data behind BTK inhibitor&#8217;s phase 3&hellip;\n","protected":false},"author":2,"featured_media":416675,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42],"tags":[154080,154081,154083,102,6591,10596,154079,14094,154078,55166,85158,71464,154082,56,54,55],"class_list":["post-416674","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-btk-inhibitor","tag-fenebrutinib","tag-fentrepid","tag-health","tag-medication","tag-multiple-sclerosis","tag-ocrevus","tag-pharma","tag-ppms","tag-rd","tag-roche","tag-sanofi","tag-tolebrutinib","tag-uk","tag-united-kingdom","tag-unitedkingdom"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/416674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=416674"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/416674\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/416675"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=416674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=416674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=416674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}